NEWS | August 9, 2023
The Radiopharmacy Department of the Central Clinic in Bad Berka (Thuringia) has obtained the manufacturing permit for three radiopharmaceutical products based on gallium. These innovative therapeutics operate on the latest theranostic principles, which means they combine diagnosis and treatment.
One of the three products, GA68-PSMA11, is used in radio-ligand therapy, a nuclear medicine treatment for prostate cancer. On the other hand, GA68-DOTATOC is utilized in the treatment of neuroendocrine tumors.
The Central Clinic in Bad Berka is recognized as an excellence center and a global leader in treating rare forms of tumors. Around 3,300 patients, including several hundred from abroad, benefit annually from the highly skilled team and the institution’s medical products manufactured to the highest standards.
Gallium plays a central role in these endeavors, and you can invest in it as a physical asset. This presents an opportunity for significant returns, along with tax-free purchase and tax-free gains after one year of holding.